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Abstract 
Purpose of the Study: Defibrotide, an orally bioavailable polydisperse oligonucleotide, has promising 
activity in hepatic veno-occlusive disease, a stem cell transplantation–related toxicity characterized by 
microangiopathy. The antithrombotic properties of defibrotide and its minimal hemorrhagic risk could 
serve for treatment of cancer-associated thrombotic complications. Given its cytoprotective effect on 
endothelium, we investigated whether defibrotide protects tumor cells from cytotoxic antitumor agents. 
Further, given its antiadhesive properties, we evaluated whether defibrotide modulates the protection 
conferred to multiple myeloma cells by bone marrow stromal cells.  
Methods-Results: Defibrotide lacks significant single-agent in vitro cytotoxicity on multiple myeloma or 
solid tumor cells and does not attenuate their in vitro response to dexamethasone, bortezomib, 
immunomodulatory thalidomide derivatives, and conventional chemotherapeutics, including melphalan 
and cyclophosphamide. Importantly, defibrotide enhances in vivo chemosensitivity of multiple myeloma 
and mammary carcinoma xenografts in animal models. In cocultures of multiple myeloma cells with bone 
marrow stromal cells in vitro, defibrotide enhances the multiple myeloma cell sensitivity to melphalan and 
dexamethasone, and decreases multiple myeloma–bone marrow stromal cell adhesion and its sequelae, 
including nuclear factor-κB activation in multiple myeloma and bone marrow stromal cells, and associated 
cytokine production. Moreover, defibrotide inhibits expression and/or function of key mediators of 
multiple myeloma interaction with bone marrow stromal cell and endothelium, including heparanase, 
angiogenic cytokines, and adhesion molecules.  
Conclusion: Defibrotide's in vivo chemosensitizing properties and lack of direct in vitro activity against 
tumor cells suggest that it favorably modulates antitumor interactions between bone marrow stromal cells 
and endothelia in the tumor microenvironment. These data support clinical studies of defibrotide in 
combination with conventional and novel therapies to potentially improve patient outcome in multiple 
myeloma and other malignancies.  
Translational Relevance 
Thrombotic and microangipathic complications of malignancy are well established, and constitute a major 
source of morbidity and mortality in cancer patients both from treatment and the disease process itself. 
Therapeutic strategies targeting endothelial injury may have the dual benefit of reducing toxicity and 
enhancing efficacy in patients. Defibrotide constitutes an orally bioavailable novel agent with 
antithrombotic properties and minimal toxicity. Our study shows that defibrotide modulates the interaction 
of stromal cells with tumor cells in a manner that increases the responsiveness of the latter to existing 
antineoplastic therapies. These data indicate that the defibrotide has considerable potential as part of 
combination treatment in specific settings, including multiple myeloma and solid tumors, such as breast 
cancer.  
Thrombotic and microangiopathic complications of malignancy are well established, and constitute a major 
source of morbidity and mortality in cancer patients because of the disease process itself and/or because of 
complications of treatment (1, 2). Therapeutic strategies targeting endothelial injury may be beneficial in 
preventing or helping the treatment of cancer-associated thrombotic complications. Defibrotide is a novel 
agent that fits such a profile. This polydisperse polydeoxyribonucleotide, derived from mammalian tissue 
(porcine mucosa) by controlled depolymerization (3), exhibits diverse biological properties, including 
antithrombotic, thrombolytic, and antiadhesive effects, and can also protect endothelial cells from 
chemotherapy-mediated cytotoxicity (3, 4). It is orally bioavailable and, importantly, because it confers no 
significant hemorrhagic risk (5), defibrotide is an attractive therapeutic option for clinical settings where 
cytoprotective and antithrombotic interventions are needed with a small margin for compromise of 
hemostasis. Hepatic veno-occlusive disease is one such clinical setting where defibrotide has been 
successfully evaluated as an important therapeutic option (6–12). This clinical syndrome of painful 
hepatomegaly, jaundice, ascites, fluid retention, and otherwise unexplained weight gain is a common 
(present in up to 60% of patients) regimen-related complication of hematopoietic stem cell transplantation, 
with severity ranging from mild, reversible disease to a severe syndrome associated with multiorgan failure 
and death (13–16). Established severe veno-occlusive disease has a mortality rate approaching 100% by 
100 days post–stem cell transplantation (13, 14, 16, 17). Veno-occlusive disease is currently considered to 
result from conditioning regimen-induced injury to the hepatic sinusoidal endothelium (18), leading to 
hepatocellular injury, stellate cell activation, and subendothelial edema, which eventually result in a triad of 
sinusoidal obstruction, hepatocellular necrosis, and venous occlusion, which are the basic pathophysiologic 
processes contributing to the clinical presentation of veno-occlusive disease (as reviewed in ref. 19). Many 
of the pleiotropic biological effects of defibrotide directly counteract the fundamental pathophysiologic 
sequelae of veno-occlusive disease and potentially confer protection to hepatic microvasculature against 
chemotherapy-mediated injury (3, 4). These considerations have provided a basis for the use of defibrotide 
for both the treatment and prevention of veno-occlusive disease (6–12).  
The clinical efficacy and safety profile of defibrotide in veno-occlusive disease prompted us to hypothesize 
that it could be used for the prevention and/or treatment of cancer-associated thromboembolic events, 
such as those emerging in the field of multiple myeloma with the use of certain types of novel agents (2). It 
was important, however, to first evaluate whether defibrotide administration could interfere with the 
antitumor activity of certain conventional or novel therapeutics for both hematologic malignancies and 
solid tumors. We specifically studied two distinct questions, both of which derive from our current 
understanding of its properties. First, we sought to determine whether defibrotide could attenuate the 
antitumor activity of various therapeutic agents, including cytotoxic chemotherapy, glucocorticoids, or 
novel therapies, including the first-in-class proteasome inhibitor bortezomib. Given its cytoprotective 
properties, specifically its ability to protect endothelial cells from chemotherapy-mediated cytotoxicity (4), 
it was critical to assess whether defibrotide could similarly protect tumor cells from cytotoxic injury, 
because defibrotide use might theoretically compromise the benefit derived from the treatment regimen. 
Second, we wanted to evaluate whether defibrotide could interfere with tumor-stromal interactions and 
their impact on the response of malignant cells to various therapeutic agents. Extensive data in various 
disease settings, most importantly in multiple myeloma as well as in other hematologic malignancies (e.g. 
various forms of leukemia) and bone metastases of various solid tumors (e.g. breast or prostate 
carcinomas; as reviewed in refs. 20, 21), have indicated that adhesion of malignant cells to bone marrow 
stromal cells can protect the tumor cells from the effects of conventional therapeutics such as cytotoxic 
chemotherapeutics or, in the case of multiple myeloma, dexamethasone. Given the antiadhesive properties 
of defibrotide in other model systems (22–26), we hypothesized that defibrotide could play a similar role in 
abrogating the tumor-stromal adhesive interaction and thus enhance the responsiveness of malignant cells 
to various antitumor agents.  
In this current study, we observed that in conventional in vitro assays, defibrotide has no direct anti–
multiple myeloma activity against multiple myeloma, breast cancer, and colon cancer cells, and does not 
attenuate the antitumor activity of several different classes of antineoplastic drugs. Interestingly, with in 
vitro cocultures of multiple myeloma cells with bone marrow stromal cells, defibrotide enhances the anti–
multiple myeloma activity of certain drugs, such as melphalan or dexamethasone. This effect is associated 
with suppressed adhesive interaction between the two cell compartments, abrogation of nuclear factor-κB 
(NF-κB) activation triggered by multiple myeloma–bone marrow stromal cell adhesion, decreased 
production of proliferative/antiapoptotic cytokines, and perturbed expression and/or function of key 
mediators of multiple myeloma–microenvironment interactions, such as heparanase, angiogenic cytokines, 
and adhesion molecules.  
Importantly, in in vivo animal models of xenografted tumor cells (from multiple myeloma or from breast 
carcinoma), administration of defibrotide increased the antitumor activity of cytotoxics, including 
cyclophosphamide. Furthermore, pharmacokinetic analyses revealed that the levels of defibrotide achieved 
in vivo in mice treated with defibrotide are consistent with the levels required (based on in vitro studies) for 
the antitumor properties of defibrotide.  
These results suggest that defibrotide administration is not only compatible with conventional and many 
novel antitumor treatment strategies, but also indicate that defibrotide exhibits microenvironment-
modulatory properties that serve to attenuate key aspects of tumor pathophysiology and drug resistance 
(e.g. tumor cell adhesion to stroma and ensuing production of antiapoptotic cytokines). This therefore 
allows defibrotide to enhance the responsiveness of tumor cells to certain conventional therapies. These 
results, coupled with the particular role of tumor-stromal interactions in the pathophysiology of multiple 
myeloma, provide the basis for further preclinical and clinical evaluation of defibrotide as an adjuvant agent 
for the management of multiple myeloma and other malignancies, including breast cancer.  
Materials and Methods 
Cell lines and primary cells. Our studies included the human breast adenocarcinoma cell line MCF-7 
(American Type Culture Collection); the human colorectal adenocarcinoma cell line HT-29 (purchased from 
the American Type Culture Collection); and a series of human multiple myeloma cell lines, including MM-
1S, MM-1R (kindly provided by Dr. Steve Rosen, Feinberg School of Medicine, Northwestern University, 
Chicago, IL), RPMI-8226 and Dox40 (kindly provided by William Dalton, Moffitt Cancer Center, Tampa, FL), 
U266 (purchased from the American Type Culture Collection), and OPM-1. Human dermal microvascular 
endothelial cells were kindly provided by the Centers for Disease Control and Prevention. Human neonatal 
dermal microvascular endothelial cells and human umbilical vein endothelial cells were purchased from 
Cambrex and propagated in EGM2-MV medium (Cambrex). Primary multiple myeloma tumor cells were 
obtained as previously described (27). Bone marrow stromal cells were cultured as previously described 
(27). All cultures were done at 37°C in a humidified atmosphere and in medium supplemented with 10% 
fetal bovine serum (FBS) and 1% penicillin-streptomycin (Invitrogen, Inc.).  
Compounds. Defibrotide was provided by Gentium. Carboplatin, melphalan, paclitaxel, vinblastine, 
vincristine, doxorubicin, dexamethasone, cyclophosphamide, BCNU, and monocrotaline (28) were 
purchased from SIGMA-Aldrich. Bortezomib (PS-341, Velcade) was obtained from Millennium 
Pharmaceuticals. CC4047 (Actimid) and CC5013 (Lenalidomide, Revlimid) were obtained from Celgene.  
Cell viability assays. MM1-S and MM1-R cells were detached from the flask using a cell scraper and were 
washed once in RPMI-2%FBS. Two thousand cells were plated per well in a 96-well format in RPMI-2%FBS. 
The cells were allowed to recover for 24 h after which they were exposed to the drugs in RPMI-2%FBS for 
96 h. MCF-7 cells and HT-29 cells were detached from the flask using 0.25% trypsin in EDTA (Invitrogen, 
Inc.) and washed once in RPMI-2%FBS. Two thousand cells were plated per well in a 96-well format in 
RPMI-2%FBS. The cells were allowed to recover for 24 h after which they were exposed to the drugs in 
RPMI-2%FBS for 96 h. Human neonatal dermal microvascular endothelial cells and human umbilical vein 
endothelial cells were detached from the flask using 0.25% trypsin in EDTA (Invitrogen, Inc.) and washed 
once in EGM2-MV. Two thousand cells were plated per well in a 96-well format in EGM2-MV. The cells 
were allowed to recover for 24 h after which they were exposed to the drugs in EGM2-MV for 96 h. The 
final volume of each well during the 96-h incubation with the drugs was 100 μL and the incubation took 
place at 37°C in a humidified atmosphere. Following the 96-h drug exposure, 10 μL of the WST-1 reagent 
(BioVision Research Products) were added to each well and incubated for 30 min at 37°C. WST-1 is a 
tetrazolium salt that is cleaved to formazan by mitochondrial dehydrogenases (29). Increased cell number 
results in increased mitochondrial dehydrogenase activity and therefore increased formazan dye formation. 
Measurement of the absorbance at 440 nm allowed quantification of the formazan dye. A reference 
wavelength of 650 nm was used per recommendations from the manufacturer of the reagent. The 650-nm 
reference absorbance value was subtracted from the 440-nm absorbance value. Background was measured 
using an empty well containing medium and no cells.  
For in vitro coculture assays of multiple myeloma cells with bone marrow stromal cells, primary multiple 
myeloma tumor cells were cultured in the presence or absence of bone marrow stromal cells, and exposed 
to defibrotide, dexamethasone or melphalan, or combination of defibrotide with dexamethasone or 
melphalan. Treatment-induced myeloma cell death was measured by flow cytometry using the Apo2.7 
mitochondrial early apoptosis marker. Multiple myeloma cells were distinguished from bone marrow 
stromal cells by staining for CD38 (30).  
In vivo studies of defibrotide as single agent and in combination with other therapeutics. To evaluate the 
potential impact of defibrotide on in vivo growth of tumors, we carried out studies in the following 
different animal models: a SCID/NOD mouse model of s.c. plasmacytoma xenografts of MM-1S cells; a 
SCID/NOD mouse model of diffuse multiple myeloma bone lesions generated by MM-1S cells; and a rat 
13762 mammary carcinoma model.  
In the SCID/NOD mouse model of s.c. plasmacytoma xenografts of MM-1S cells, 60 male SCID/NOD mice (6-
8 wk old) were irradiated (450 rads) and, 24 h later, injected s.c. with 5 × 106 MM-1S human multiple 
myeloma cells. Upon formation of palpable tumors, the mice were randomly assigned to 6 cohorts (10 mice 
each) receiving (a) vehicle; (b) defibrotide i.v. 450 mg/kg b.i.d.; (c) melphalan 2.5 mg/kg i.p. once weekly; 
(d) cyclophosphamide 50 mg/kg i.p., on days 8, 10, 12, 20, 22, and 24; (e) and (f) combinations of 
defibrotide (300 mg/kg i.v.) with melphalan or cyclophosphamide, respectively. Mice were monitored every 
3 d for body weight, potential toxicity, and electronic caliper-based tumor volumes.  
In the SCID/NOD mouse model of diffuse multiple myeloma bone lesions, 20 male SCID/NOD mice (6-8 wk 
old) were irradiated (450 rads) and, 24 h later, injected i.v. with 1 × 106 MM-1S human multiple myeloma 
cells, leading to formation of diffuse multiple myeloma tumors, as previously described (31). The mice were 
then randomly assigned to four cohorts (five mice each) receiving (a) vehicle; (b) defibrotide orally 45 
mg/kg b.i.d.; (c) melphalan 2.5 mg/kg i.p. once weekly; and (d) combinations of defibrotide (45 mg/kg) with 
melphalan. The mice were monitored for body weight and potential toxicity. If they developed signs of 
morbidity (e.g. hind limb paralysis due to tumor growth in the spine, infection, major bleeding, etc.), they 
were sacrificed by CO2 inhalation according to Animal Care Use Committee guidelines. The primary end 
point for this model was the overall survival of mice (defined as time between initiation of treatment and 
sacrifice).  
Rat mammary adenocarcinoma 13762 is a carcinogen-induced tumor syngeneic for the female Fisher 344 
rat. For experiments, 13762 mammary carcinoma cells (2 × 106) prepared from a brei of donor tumors were 
implanted s.c. into a hind leg of female Fisher 344 rats weighing between 140 and 160 g (Taconic Farms). 
The animals were housed and handled in accordance with Animal Care and Use Committee guidelines. The 
13762 tumor grew to 100 mm3 in about 8 d (32, 33). Each group consisted of five rats. Defibrotide 
administration was initiated either at the same time as cytotoxic treatment or 2 d after the first dose of 
cytotoxic treatment. Monocrotaline (350 mg/kg) or BCNU (150 mg/kg) was administered by i.p. injection on 
days 8 and 18 post–tumor cell implant (28). Defibrotide (200 mg/kg) was administered twice per day by i.v. 
injection on days 8 through 26 or on days 10 through 26. Tumor volumes were calculated using the formula 
(w2 × l)/2 where w is the width of the tumor and l is the length of the tumor. Individual rats were weighed 
and tumor measurements taken by calipers twice weekly. The antitumor activity of the treatments was 
determined by calculating tumor growth delay (T-C) in days. Tumor growth delay was obtained by 
determining the difference between treatment and control group mean tumor growth in days at a 
predetermined tumor volume. The data are presented as means ± SE. caliper-based tumor volumes.  
Pharmacokinetic studies. Eight-week-old male Fisher 344 rats (Charles River Laboratories) were treated (10 
mice per treatment cohort), either orally or i.v., with defibrotide (48 mg/kg). Peripheral blood plasma 
samples were serially collected (0-8 h) via preinserted jugular vein catheter for determination of 
pharmacokinetic profile by high-pressure liquid chromatography analyses and validation by agarose gel 
determination, as previously described. Briefly, blood samples taken before the administration (basal 
condition) of defibrotide and at 1, 3, 5, 10, 20, 30, 40 min and 1, 2, and 4 h after administration. The 
anticoagulated blood was centrifuged to obtain the plasma samples and 1 mL of N perchloric acid was 
added to each 1 mL of plasma. After stirring, the sample was heated for 15 min in water bath at 70°C 
degrees. The samples were centrifuged at 3,000 g. The pellet was discarded and 1 mL of diphenylamine 
reagent [100 mL of glacial acetic acid + 1.5 g diphenylamine + 1.5 mL conc. sulfuric acid and 0.6 mL of 0.16% 
(w/v) solution of acetaldehyde in water] was added to 1 mL of supernatant. The samples were incubated 
for 17 to 20 h at 25°C to 30°C. The absorbance of the samples at 600 nm was read in spectrophotometer. A 
standard curve was also prepared with defibrotide dissolved in plasma taken from control animals. For the 
high-pressure liquid chromatography determination, plasma samples were heated to 70°C for 3 min and 
were then left to cool to 37°C. After adding 12 mg trypsin, samples were kept in water bath at 37°C for 5.5 
h and then diluted with 10 mmol/L phosphate buffer, pH 7.0-Mobile phase of Chromatography, injected 
into liquid phase chromatograph. For agarose gel determination, plasma samples were heated to 70°C for 
about 3 min, then left cool to 37°C. After addition of trypsin, the samples were kept in water bath at 37°C 
for 5.5 h and then were diluted with Tris-acetate buffer, pH 7.8, to give concentrations of defibrotide from 
10 to 50 ug/mL. The samples were run in 2-mm thick 0.5% agarose gel in 5% sorbitol in acetate buffer, pH 
7.8 at >4°C, 90V, 30 to 35mA for 75 min, in a LKB model 2117 multiphor II electrophoretic chamber (from 
reference materials). The gels were stained with acridine orange (0.006% w/v), in 0.01 mol/L phosphate 
buffer, pH 7.0. The gel slabs, after drying, were analyzed by a thin-layer chromatography scanner photo 
densitometer. The measurements with carried at 470 nm.  
Molecular profiling studies and functional experiments. mRNA levels of heparanase, vascular endothelial 
growth factor (VEGF), fibroblast growth factor 2 (FGF-2), ICAM-1, and E-selectin were measured through 
Syber-green Real-Time PCR of cDNA prepared from target cell populations (multiple myeloma cells, 
endothelial cells) treated with and without defibrotide using the following primers heparanase: F- 
TCACCATTGACGCCAACCT and R- CTTTGCAGAACCCAGGAGGAT; VEGF: F- CTACCTCCACCATGCCAAGT and R- 
GCAGTAGCTGCGCTGATAGA; FGF-2: F- CCACTTCAAGGACCCCAAG and R- ATAGCCAGGTAACGGTTAGC; ICAM-
1: F- CTGTTCCCAGGACCTGGCAAT and R- AGGCAGGAGCAACTCCTTTTTA; E-selectin: F- 
CTCTGACAGAAGAAGCCAAG and R- ACTTGAGTCCACTGAAGCCA; and β-actin: F- 
TCACCCACACTGTGCCCATCTACGA and R- CAGCGGAACCGCTCATTGCCAATGG (housekeeping gene). 
Intracellular levels of heparanase were measured by intracellular flow cytometry through FACSCalibur flow 
cytometer and the CellQuest analysis program (Becton Dickinson) using goat polyclonal antihuman 
heparanase antibodies (Santa Cruz Biotecnology Inc). Omitting the first antibody served as a negative 
control to detect unspecific fluorescence. Heparanase enzymatic activity was measured in extracts of 
defibrotide-treated versus control cells by a commercial heparan degrading enzymatic kit (Takara-bio Inc.).  
Adhesion assays of multiple myeloma cells on bone marrow stromal cells were done by using carboxyl 
fluorescent succinimidyl ester (CFSE) labeling of multiple myeloma cells with the CellTrace CFSE Cell 
Proliferation Kit (Molecular Probes) according to the instructions of the manufacturer. After CFSE labeling, 
multiple myeloma cells were plated in optical 96-well plates on which bone marrow stromal cells had been 
preseeded and defibrotide or control medium. At the conclusion of the cocultures, each well was processed 
by gentle aspiration of their supernatant and washing with 1× PBS. After repeating the aspiration and 
addition of 1×PBS twice, the plates were read in a fluorescence plate reader (excitation and emission 
wavelengths of 485 and 520 nm, respectively) to evaluate the percentage of fluorescent multiple myeloma 
cells that remained adhered to bone marrow stromal cells in the presence versus absence of defibrotide 
treatment.  
NF-kB–binding ELISAs for evaluation of transcription factor activity were carried out with NF-kB 
transcription factor ELISA kits (Active Motif) as previously described. Interleukin 6 (IL-6) and VEGF protein 
levels were measured with corresponding ELISA kits (R&D Diagnostics) according to the instructions of the 
manufacturer.  
Tumor cell invasion assays were done to assess in vitro the invasive potential of multiple myeloma cells. 
Briefly, multiple myeloma cells overexpressing heparanase or supplemented with heparanase recombinant 
enzyme (GenWay Biotech Inc.) treated with and without defibrotide were layered on the top chamber of a 
dual-chamber in vitro culture system (Becton Dickinson). The two chambers were separated by a 
polyethylene terephthalate membrane and matrigel, and the number of multiple myeloma cells that 
invaded the matrigel and the polyethylene terephthalate membrane towards the lower chamber were 
evaluated by fluorescence microscopy and fluorescence plate readers. The invasive potential of the 
multiple myeloma cells was assessed on the basis of the number of fluorescent (calcein-labeled) multiple 
myeloma cells penetrating the lower chamber. In order to have multiple myeloma cells overexpressing 
heparanase, heparanase cDNA (HPSE1) was subcloned into the pcDNA3.1/CT-GFP (Invitrogen) vector to 
give an in-frame COOH-terminal green fluorescent protein fusion construct. The pcDNA3.1/CT-GFP/HPSE1 
construct was transfected into the RPMI 8226 human multiple myeloma cells using Lipofectin reagents 
(Invitrogen) following the manufacturer's instructions.  
Statistical methods. In the cell viability assays, each experimental point was set up in duplicate wells and 
each assay was repeated identically and independently at least once and, for each experiment, two 
repetitions of the assay were combined into a single data set in which each experimental point was 
represented by four values. The mean and SD of these four values were determined for each experimental 
point. The final data were expressed as a percentage of the proliferation that took place in control wells 
where cells were not exposed to any drugs. IC50 values were determined for each experiment. In the in vivo 
models, the overall survival of mice was evaluated with Kaplan-Meier survival analyses, and differences 
between the various cohorts of each experiment were assessed by log-rank tests.  
Results 
Assessment of direct effects of defibrotide on in vitro viability of tumor cells and endothelial cells. We did 
colorimetric survival assays to test the in vitro effects of defibrotide (0-1,000 μg/mL for 96 hours) on human 
multiple myeloma cell lines. We observed that exposure to defibrotide did not significantly affect the in 
vitro viability of these cell lines (except for a modest decline in viability of MM-1R cells treated with the 
highest concentration of defibrotide tested, i.e. 1,000 μg/mL; Fig. 1A and Supplementary Fig. S1). We 
extended these observations to other tumor types (e.g. the breast carcinoma cell line MCF-7 and the colon 
cancer cell line HT-29; Supplementary Fig. S1C and S1D, respectively); to two different endothelial cell 
models (human neonatal dermal microvascular endothelial cells and human umbilical vein endothelial cells; 
Supplementary Fig. S1E and S1F, respectively); and to additional well-characterized human multiple 
myeloma cell line models (e.g. OPM-1, Dox40, and RPMI-8226/S; Supplementary Fig. S1G).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  
 
In vitro viability of multiple myeloma cell lines treated with defibrotide alone or its combination or novel 
anti–multiple myeloma agents. A, results of in vitro defibrotide treatment of multiple myeloma cell lines, 
including MM-1S, its dexamethasone-resistant subline MM-1R, the chemosensitive RPMI-8226/S and its 
doxorubucin-resistant subline Dox40, as well as the OPM-1 cells. B, WST-1 assays were done to assess the 
putative impact of defibrotide on the in vitro response of multiple myeloma cells to diverse agents, 
including melphalan, doxorubicin, bortezomib (PS341), the IMID pomalidomide (CC-4047), and 
dexamethasone. These results represent the combination of two separate independent experiments.  
Evaluation of in vitro effects of combinations of defibrotide with diverse antitumor agents. Colorimetric 
survival assays (with WST-1) were done to evaluate whether defibrotide can modulate the activity of 
various therapeutics against multiple myeloma cells, cell lines from other tumor models, or endothelial 
cells. We specifically evaluated the in vitro effects of combinations of defibrotide with a series of antitumor 
agents, including dexamethasone, the proteasome inhibitor bortezomib (PS-341), the immunomodulatory 
derivatives CC-5013 (lenalidomide, Revlimid), and CC-4047 (pomalidomide, Actmid), as well as carboplatin, 
melphalan, paclitaxel, vinblastine, vincristine, and doxorubicin. When used as single agents, carboplatin, 
melphalan, paclitaxel, vinblastine, vincristine, doxorubicin, bortezomib, CC-4047, and dexamethasone 
significantly decreased the numbers of viable MM-1S (Fig. 1, Supplementary Fig. S2 and Supplementary 
Table S1). When these MM-1S cells were exposed to a combination of 100 μg/mL defibrotide with 
increasing concentrations of carboplatin, melphalan, paclitaxel, vinblastine, vincristine, bortezomib, CC-
4047, CC-5013, or dexamethasone, the effect of each one of these combinations on the viability of MM-1S 
was similar to the effect observed with each agent alone in the absence of defibrotide (Fig. 1, 
Supplementary Fig. S2, and Supplementary Table S1). We then extended these combination studies to 
other types of tumor cells and to endothelial cells and observed that defibrotide also did not sensitize MCF-
7, HT-29, human neonatal dermal microvascular endothelial cells, or human umbilical vein endothelial cells 
to any of these agents or antagonize the activity of any of these agents (Supplementary Table S1). The only 
exception to that general pattern was observed in combinations of defibrotide with doxorubicin: when 
defibrotide was used (at a fixed concentration of 100 μg./mL) in combination with doxorubicin, the 
decrease in MM-1S cell viability was significantly attenuated, with an IC50 of 20 nmol/L in the absence of 
defibrotide and of >400 nmol/L in the presence of defibrotide (Fig. 1, and Supplementary Table S1). 
Similarly, defibrotide significantly increased the IC50 value of doxorubicin against MCF-7 cells (IC50 value of 
20 nmol/L in the absence of defibrotide versus 550 nmol/L in the presence of defibrotide), HT-29 cells (IC50 
value of 60 versus 25,000 nmol/L, respectively), human neonatal dermal microvascular endothelial cells 
(200 versus 2900 nmol/L respectively), and human umbilical vein endothelial cells (200 versus 1,100 
nmol/L, respectively; Supplementary Table S1).  
We also evaluated whether defibrotide could revert the resistance to dexamethasone. To this end, we 
treated the MM-1R cells (a dexamethasone-resistant subline of the MM-1S cells) with dexamethasone 
alone versus a combination of dexamethasone and defibrotide. We observed that dexamethasone alone 
failed (at concentrations up to 1 μmol/L) to inhibit the survival of MM-1R cells (whereas it inhibited MM-1S 
cell viability with an IC50 of 12 nmol/L) and that in the presence of defibrotide, the IC50 for inhibition of MM-
1R cell viability by was still >1 μmol/L, suggesting that defibrotide does not overcome the dexamethasone 
resistance of MM-1R cells (Supplementary Fig. S2F and Supplementary Table S1).  
In vivo antitumor activity of defibrotide. The in vivo antitumor activity of defibrotide was evaluated in a 
series of different animal models of tumor growth, including a SCID/NOD mouse model of s.c. 
plasmacytoma xenografts of MM-1S cells, a SCID/NOD mouse model of diffuse multiple myeloma bone 
lesions generated by MM-1S cells, and a rat 13762 mammary carcinoma model. In each one of these 
models, tumor-bearing mice were treated with defibrotide alone, with various antitumor therapeutics (the 
choice of which depended on the particular tumor type that was studied), with combinations of defibrotide 
with these antitumor therapeutics, or with the respective vehicles. In the first of these models, SCID/NOD 
mice bearing s.c. plasmacytoma xenografts of MM-1S cells were randomly assigned to cohorts treated with 
vehicle, melphalan alone, cyclophosphamide alone, defibrotide alone, defibrotide plus melphalan, and 
defibrotide plus cyclophosphamide. Defibrotide, either as single agent or in combination with melphalan or 
cyclophosphamide, was well tolerated without hemorrhagic complications or body weight loss (P > 0.05) in 
all groups. The major end points for efficacy were (a) tumor volume changes and (b) overall survival (time-
to-sacrifice, done when tumor diameters >2 cm). Defibrotide treatment resulted in significantly lower 
tumor volumes than in control mice (P < 0.05 for all comparisons by ANOVA and posthoc tests). The 
combination of defibrotide with melphalan or cyclophosphamide induced significantly lower tumor 
volumes than the respective single-agent cytotoxic chemotherapy (Fig. 2A and B ; P < 0.05 for all 
comparisons). Kaplan-Meier survival analyses showed that defibrotide administration, either as single 
agent or in combination with cytotoxic chemotherapy (melphalan or cyclophosphamide), was associated 
with statistically significant prolongation of overall survival, in comparison with vehicle-treated control 
group or melphalan- or cyclophosphamide-treated groups, respectively (P < 0.001 for all comparisons, log-
rank test).  
Fig. 2.  
 
In vivo studies of defibrotide in combination with other antitumor agents. Changes in tumor volume over 
time in mice xenografted with human MM-1S cells (s.c. xenograft model in A and B, and model of diffuse 
multiple myeloma lesions in C) and treated with defibrotide either alone or in combination with melphalan 
(A and C) or cyclophosphamide (B).  
In the second model, SCID/NOD mice injected i.v. with multiple myeloma cells to generate diffuse multiple 
myeloma bone lesions were randomly assigned to cohorts treated with vehicle, melphalan alone, 
defibrotide alone, and defibrotide plus melphalan. In this model, the combination of defibrotide plus 
melphalan led to significant prolongation in overall survival of mice compared with each drug alone (Fig. 
2C; P = 0.0018, log-rank test).  
In the third tumor model of rat 13762 mammary carcinoma, tumor-bearing animals were treated with 
monocrotaline alone, BCNU alone, or with combinations thereof with defibrotide. The primary endpoint in 
this model was the growth delay that was achieved in each treatment cohort, defined as the difference in 
the number of days necessary for mice in the control cohort to reach tumor volumes of 500 mm3 compared 
with mice in the respective treatment cohort (day 0 was the day of tumor cell implantation and 
chemotherapy was administered on days 8 and 18; Supplementary Table S2). In this model, the growth 
delay achieved in the cohorts of mice treated with the combination of defibrotide with either 
monocrotaline or BCNU was longer than the growth delay in the cohorts treated with the respective 
cytotoxic chemotherapeutic alone.  
Preclinical pharmacokinetic studies of defibrotide. We evaluated the in vivo pharmacokinetic profile of 
defibrotide in one of our in vivo animal models. Specifically, blood samples were collected at specific 
intervals (as described in Materials and Methods) from preinserted jugular vein catheters in Fisher male 
rats treated with defibrotide (48 mg/kg single dose) either through oral or i.v. route (Supplementary Fig. 
S3). Plasma levels of defibrotide were evaluated by high-pressure liquid chromatography and agarose gel 
determination and provided highly consistent pharmacokinetic data between the two techniques (with 
mean and median variability of measurement of 8.07% and 7.89%, respectively). With i.v. and oral 
administration, peak defibrotide levels (Cmax) were 1,253 and 474 μg/mL, and area under the curve (AUC0-240 
min) 14.71 and 17.19 μg × min/L, respectively. Time to Cmax was ∼30 min for oral administration and 
returned to undetectable levels by 240 min posttreatment for both oral and i.v treatment (Supplementary 
Fig. S3). These results suggest that the levels of defibrotide that are required for some of the mechanistic 
sequelae of defibrotide in our preclinical in vitro models are achievable in vivo and could be involved in the 
in vivo mechanism(s) whereby defibrotide sensitizes multiple myeloma tumor cells to certain antitumor 
therapies.  
Effect of defibrotide on in vitro cocultures of multiple myeloma cells with bone marrow stromal cells. 
Adhesion to bone marrow stromal cells attenuates the response of multiple myeloma cells to conventional 
antineoplastic agents, e.g. dexamethasone and cytotoxic chemotherapeutics (as reviewed in ref. 21). 
Because of the proposed antiadhesive properties of defibrotide in the context of vascular biology (22–26), 
we hypothesized that defibrotide may have a similar effect in the setting of tumor-stromal interactions in 
multiple myeloma. We thus evaluated whether defibrotide can modify the response of primary multiple 
myeloma cells to such conventional therapeutics in the context of stromal coculture. Primary multiple 
myeloma tumor cells (CD38 positive) isolated from multiple myeloma patients were cocultured with bone 
marrow stromal cells (CD38 negative) and flow cytometry was used to evaluate the fraction of dead cells 
(Apo2.7-PE positive) within the CD38-positive multiple myeloma cells. Treatment with defibrotide (100 
μg/mL) alone did not trigger significant changes in multiple myeloma cell viability compared with 
defibrotide-free control cultures, either in the presence or absence of bone marrow stromal cells (Fig. 3 and 
Supplementary Fig. S4). Furthermore, in the absence of bone marrow stromal cells, defibrotide 
administration did not significantly increase the percentage killing of multiple myeloma cells exposed to 
dexamethasone (Fig. 3A and Supplementary Fig. S4A) or melphalan (Fig. 3B and Supplementary Fig. S4B), 
consistent with the colorimetric survival assay results obtained with multiple myeloma cell lines. When 
multiple myeloma cells were treated with dexamethasone or melphalan alone in the presence of bone 
marrow stromal cells, the percentage multiple myeloma cell killing was in most cases significantly lower 
compared with single-agent dexamethasone- or melphalan-induced cell killing in the absence of bone 
marrow stromal cells. However, in the context of multiple myeloma cell coculture with bone marrow 
stromal cells, the combination of defibrotide with dexamethasone (Fig. 3A and Supplementary Fig. S4A) or 
melphalan (Fig. 3B and Supplementary Fig. S4B) significantly increased in a large proportion of cases the 
percentage cell killing of multiple myeloma cells compared with treatment with dexamethasone or 
melphalan alone.  
 Fig. 3.  
 
Defibrotide (DF) treatment enhances the anti–multiple myeloma activity of conventional therapeutics in 
the context of multiple myeloma–bone marrow stromal cell interactions. Illustrative examples of results 
from treatment of primary multiple myeloma cells with dexamethasone (Dex, A) or melphalan (Mel, B), in 
the presence or absence of bone marrow stromal cells (SCs), with or without treatment with defibrotide. 
Among multiple myeloma samples that exhibit constitutive responsiveness to these agents in the absence 
of stroma, but significantly less pronounced response in multiple myeloma–bone marrow stromal cell 
cocultures, defibrotide is able to lead to variable degrees of sensitization to these agents in the presence of 
stromal cells. In each panel, primary samples 3 to 6 are examples of how defibrotide treatment can 
increase the presence of stromal cells higher response to treatment with dexamethasone or melphalan, 
respectively.  
Cellular and molecular sequelae of defibrotide treatment in the multiple myeloma-bone marrow stromal 
cell coculture. To evaluate the mechanisms whereby defibrotide can attenuate protective effects conferred 
with multiple myeloma cells by bone marrow stromal cells, we did in vitro cell adhesion assays and 
observed that defibrotide significantly decreased the adhesion of multiple myeloma cells to bone marrow 
stromal cells (Fig. 4A ). The multiple myeloma cell adhesion to bone marrow stromal cells has been 
previously associated with increased transcriptional activity of NF-κB in both cellular compartments (34, 
35), leading to increased secretion of antiapoptotic cytokines (such as IL-6) and proangiogenic growth 
factors (such as VEGF; ref. 27). We therefore hypothesized that the decrease in multiple myeloma–bone 
marrow stromal cell adhesion could have an impact on these molecular sequelae. Indeed, separate assays 
in the multiple myeloma cell compartment versus bone marrow stromal cells of the in vitro coculture 
model showed that defibrotide treatment decreased the NF-κB transcriptional activity in both multiple 
myeloma cells (Supplementary Fig. S5A) and bone marrow stromal cells (Supplementary Fig. S5B). This 
finding was also associated with suppression in secretion of IL-6 (Fig. 4B) and VEGF (Fig. 4C), consistent with 
the antiadhesive properties of defibrotide and with the impact of multiple myeloma–bone marrow stromal 
cell adhesion on secretion of these cytokines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.  
 
Defibrotide (DF) modulates multiple myeloma (MM) cell adhesion to bone marrow stromal cells (BMSC or 
SCs) and its sequelae. In vitro adhesion assays (with CFSE labeling of multiple myeloma cells and 
quantification of adhesion with fluorescence plate reader) show that defibrotide treatment decreases the 
adhesion of primary multiple myeloma tumor cells to bone marrow stromal cells (A). Furthermore, 
defibrotide treatment suppresses the increase, triggered by multiple myeloma–bone marrow stromal cell 
interaction, in secretion of IL-6 (B) or VEGF (C). Cytokine levels in B and C are expressed, in each 
experiment, as percentage of levels in cultures of stromal cells alone.  
Defibrotide modulates the expression and function of heparanase. Heparanase is an enzyme that cleaves 
heparan sulfate chains of proteoglycans, and its expression has been associated with increased growth, 
metastasis, and angiogenesis of several tumor types, including multiple myeloma (36–40). Because of the 
increasing interest in the potential role of heparanase as a mediator of tumor-microenvironment 
interactions in multiple myeloma, we evaluated whether defibrotide modulates the biological activity of 
heparanase. We first confirmed that defibrotide treatment suppresses the expression of heparanase 
transcripts (assessed by real-time reverse transcription-PCR) in RPMI-8226 and U266 multiple myeloma 
cells (Fig. 5A and Supplementary Fig. S6A); and decreases the intracellular protein expression of heparanase 
(as evaluated by intracellular flow cytometry; Fig. 5B). These effects correlated with defibrotide-induced 
decreases in heparanase activity in cultures of RPMI-8226 cells (Fig. 5C) and U266 cells (Supplementary Fig. 
S6B). To further probe the functional significance of these observations, we evaluated the impact of 
defibrotide on an in vitro tumor invasion assay in dual-chamber culture system, in which multiple myeloma 
cells labeled with calcein were incubated in the upper chamber of the system. Exogeneous addition of 
recombinant human heparanase in the culture (Fig. 6A ) or transfection of RPMI-8226 cells with heparanase 
construct (Fig. 6B) increased the invasion potential of the multiple myeloma cells, but in both cases 
defibrotide treatment abrogated that effect (Fig. 6A and B).  
 
Fig. 5.  
 
Defibrotide (DF) treatment suppresses the expression and function of heparanase. Reverse transcription-
PCR was done as described in Material and Methods. Results are expressed as mean mRNA heparanase 
level normalized by β-actin housekeeping gene. Defibrotide treatment suppresses the levels of heparanase 
transcript in RPMI-8226 (A) multiple myeloma cells. Furthermore, defibrotide suppresses the intracellular 
protein expression of heparanase, measured by flow cytometric analysis (B), as well as the heparanase 
activity in cellular extracts of RPMI-8226 (C) multiple myeloma cells. Student's test: *P < 0.05 and **P < 0.01.  
 
Fig. 6.  
 
Defibrotide (DF) modulates the invasive potential of multiple myeloma cells and the molecular sequelae of 
their interactions with endothelial cells. The invasive potential of multiple myeloma cells was assessed in 
vitro on the basis of their ability to invade from the top to the bottom chamber of a dual-chamber in vitro 
culture system when these two chambers are separated by matrigel and a polyethylene terephthalate 
membrane. The invasive potential of the multiple myeloma cells was enhanced by either exogenous 
addition of heparanase (HSPE) in the culture (A) or multiple myeloma cell transfection with heparanase 
construct (B), but was suppressed, in both cases, by defibrotide treatment. The interaction with multiple 
myeloma cells triggers in human microvascular endothelial cells (HMECs) the up-regulation of transcripts 
for heparanase (C); VEGF and FGF-2 (D), but these events are suppressed by defibrotide treatment. 
Student's test: §,*P < 0.05 and §§,**P < 0.01.  
Defibrotide modulates the molecular events triggered by interaction of endothelial cells with multiple 
myeloma cells. We established an in vitro system where multiple myeloma cells and human dermal 
microvascular endothelial cells were cultured in close proximity to each other, with the human dermal 
microvascular endothelial cells cultured in the lower chamber of a dual-chamber in vitro system, while the 
upper chamber contained either medium only (control) or medium with multiple myeloma cells. In that 
system, the human dermal microvascular endothelial cells were cultured (for 48 hours) and after removal 
of the upper chamber inset, the human dermal microvascular endothelial cells and the multiple myeloma 
cells were separately harvested and processed for mRNA extraction and Real-Time PCR analysis for 
heparanase transcripts. In this experiment, interaction with multiple myeloma cells triggered in human 
dermal microvascular endothelial cells a significant increase in heparanase expression (Fig. 6C), which was 
abrogated by defibrotide. In this same system, the interaction of human dermal microvascular endothelial 
cells with multiple myeloma cells triggered increased gene expression of VEGF, FGF-2 (Fig. 6D), ICAM-1 
(Supplementary Fig. S7A), and E-selectin (Supplementary Fig. S7B) in human dermal microvascular 
endothelial cells; as well as increased expression of heparanase, VEGF, and FGF-2 in multiple myeloma cells 
(Supplementary Fig. S7C). Importantly, treatment with defibrotide was able to suppress these events 
triggered by human dermal microvascular endothelial cell–multiple myeloma interaction (Fig. 6D and 
Supplementary Fig. S7).  
Discussion 
The key focus of this study was to evaluate whether defibrotide can be administered concomitantly with 
various antineoplastic agents currently used for the management of multiple myeloma and other 
neoplasias. Defibrotide has clinical activity for the treatment of severe veno-occlusive disease (6, 7, 10, 41), 
a clinical setting which historically has >90% mortality rate (42). Among the diverse properties of 
defibrotide, its antithrombotic effects, and relative lack of severe hemorrhage or other serious treatment-
related toxicity, led us to hypothesize that defibrotide may be an attractive agent for prevention and/or 
treatment of thromboembolic complications associated with cancer treatment (2). Specifically, we 
hypothesized that the pleiotropic features of defibrotide that confer protection of endothelial cells from 
diverse forms of injury could be useful in treating vascular damage associated with neoplasia-related 
prothrombotic states. For extensive clinical evaluation of defibrotide in cancer-related clinical settings to 
occur, it was essential to address whether its administration is compatible with anticancer treatments. In 
particular, given the known protective effect of defibrotide on the endothelium, it would be potentially 
detrimental if defibrotide were to extend similar protective effects to neoplastic tissues. Specifically, if 
neoplastic cells were among those tissues protected by defibrotide, its administration (e.g. as prophylaxis 
against development of veno-occlusive disease following high-dose chemotherapy and stem cell 
transplantation), might theoretically counteract the antitumor effects of the cytotoxic conditioning 
regimen, thus defeating the purpose of the stem cell transplantation approach.  
Our present study indicates that defibrotide does not counteract the antitumor activity of several cytotoxic 
chemotherapy agents commonly used in the management of hematologic malignancies (including multiple 
myeloma) and/or solid tumors. This observation was made in in vitro experiments with cell lines from 
multiple myeloma, and colon and breast carcinoma. We also confirmed that defibrotide does not blunt the 
anti–multiple myeloma effect of dexamethasone or the proteasome inhibitor borterzomib (PS-341). 
Notably, among the diverse classes of anticancer drugs that we tested, defibrotide attenuated the 
antitumor effect (in multiple myeloma or other tumor models) of doxorubicin. Further studies in our group 
are addressing whether this effect represents a specific feature of doxorubicin or a phenomenon pertinent 
to the entire class of anthracyclines. It is possible that the three-dimensional structure of defibrotide 
retains sufficient similarity to the “stacked ring” structure of its precursor DNA to allow for anthracyclines 
to intercalate with defibrotide, similar to anthracycline intercalation with DNA strands in target cells. For 
the moment, based on these results, we would suggest caution in terms of concurrent use of defibrotide 
with doxorubicin or other anthracyclines.  
While evaluating the possible impact defibrotide on antitumor activities of various classes of agents, we 
observed no inhibition of their antineoplastic activity. However we also did not observe a pronounced 
sensitization of tumor cells to these drug classes (an exception included a modest sensitization of some, but 
not all, solid tumor cell lines to certain platinum agents). Furthermore, we observed that defibrotide had no 
significant effect on tumor cell survival as a single agent. These results taken together suggest that, in 
respect to the tumor models and majority of cancer drug classes that we tested, defibrotide does not 
exhibit direct antitumor effects but also does not function to decrease drug responsiveness in these 
neoplastic cells.  
However, conventional assays for in vitro drug sensitivity of tumor cells cultured in isolation have the key 
limitation that they do not take into account the interactions of tumor cells with their local 
microenvironment. It is known that responses of multiple myeloma and other tumor types to various 
anticancer therapies can be attenuated by cell adhesion–mediated and cytokine/growth factor–driven 
interactions of tumor cells with their local microenvironment (reviewed in ref. 21). For instance, multiple 
myeloma cell adhesion to bone marrow stromal cells stimulates paracrine (bone marrow stromal cell–
derived) and/or autocrine (multiple myeloma cell–derived) production of anti-apoptotic cytokines, such as 
IL-6; as well as triggers direct cell-to-cell contact–mediated antiapoptotic signaling cascades in multiple 
myeloma cells (21). The composite effect of these interactions is to attenuate the response of multiple 
myeloma cells to various conventional treatments, such as dexamethasone or cytotoxic chemotherapeutics 
(21). Because this effect is mediated at least in part by adhesion of multiple myeloma cells on bone marrow 
stromal cells, we hypothesized that the antiadhesive properties of defibrotide (22) could potentially serve 
to modulate multiple myeloma–bone marrow stromal cell interactions and so sensitize multiple myeloma 
cells to some of these therapeutics against which the bone marrow milieu and its stromal cells confer 
protection.  
Our in vitro and in vivo studies support this hypothesis. In ex vivo cocultures of multiple myeloma cells with 
bone marrow stromal cells, defibrotide had no significant single-agent effect on multiple myeloma cell 
viability, either in the presence or absence of bone marrow stromal cells, and had no sensitizing effect on 
multiple myeloma cells exposed to melphalan in the absence of bone marrow stromal cells. However, the 
protection conferred by bone marrow stromal cells to multiple myeloma cells against dexamethasone or 
melphalan was significantly suppressed by defibrotide. Further studies at a mechanistic level showed that 
defibrotide treatment of multiple myeloma–bone marrow stromal cell cocultures is associated with 
decreased adhesion of multiple myeloma cells to bone marrow stromal cells and suppression of several key 
molecular events triggered by multiple myeloma–bone marrow stromal cell adhesion, including IL-6 and 
VEGF secretion, and NF-κB activation in both the multiple myeloma and bone marrow stromal cell 
compartments. IL-6 secretion and NF-κB activation play well-characterized roles in conferring decreased 
sensitivity of multiple myeloma cells (or other tumor models) to proapoptotic agents, including 
dexamethasone and/or cytotoxic chemotherapy.  
Our in vitro studies support the notion that the effects of defibrotide extend to other aspects of tumor-
microenvironment functional interface, such as the interaction of multiple myeloma cells with human 
dermal microvascular endothelial cells and the invasiveness of multiple myeloma cells. Although interaction 
of multiple myeloma cells with human microvascular endothelial cells up-regulates the expression of 
heparanase, VEGF, FGF-2, ICAM-1, and E-selectin in human dermal microvascular endothelial cells, and of 
VEGF and FGF-2 in multiple myeloma cells, these events are suppressed by defibrotide treatment. In 
addition, defibrotide suppresses in multiple myeloma cell cultures the transcript and protein expression of 
heparanase, as well as its enzymatic activity. Recent studies in multiple myeloma and solid tumors have 
identified heparanase as an important regulator of tumor cell proliferation, invasiveness, and metastatic 
potential (36, 38, 40). To further evaluate the functional significance of the effects of defibrotide on 
heparanase, we did ex vivo tumor cell invasion assays, which showed that defibrotide treatment 
suppressed the increase in multiple myeloma cell invasive potential triggered by either exogenous addition 
of heparanase in the culture or multiple myeloma cell transfection with heparanase construct.  
Importantly, defibrotide exhibits antitumor activity in vivo. We observed in three different animal models 
that defibrotide can sensitize multiple myeloma or solid tumor cells to various cytotoxic agents, without 
significant side effects. In addition, we did in vivo pharmacokinetic studies of defibrotide (both in oral and 
i.v. administration) that suggest that the defibrotide levels required for in vitro tumor sensitization to 
dexamethasone and cytotoxic chemotherapy are achievable in vivo.  
Our in vitro results indicate that the ability of defibrotide to enhance the antitumor activity of 
dexamethasone or chemotherapeutics in the context of multiple myeloma cell interactions with their 
milieu is multifactorial. Specifically, defibrotide modulates tumor cell interactions with different 
nonmalignant accessory cell compartments of the local milieu (e.g. bone marrow stromal cells and 
endothelial cells), influences the protection that these cells can confer to multiple myeloma cells against 
conventional antitumor agents, interferes with the ability of tumor cells and their microenvironment to 
trigger cytokine production necessary for recruitment of new blood vessels without significant direct 
cytotoxic effect on endothelial cells, and targets heparanase and its role in facilitating the invasiveness 
potential of tumor cells. These tumor-microenvironment interactions are not exclusive to multiple 
myeloma, but are features of a broad spectrum of hematologic malignancies and solid tumors (43–45). 
Therefore, the activity of defibrotide in both multiple myeloma and solid tumor models suggests that its 
antitumor properties may have applications in a broad spectrum of neoplasias. With its proven 
chemoprotective activity towards normal tissues, clinically leveraged to treat veno-occlusive disease (6–9, 
11) and its activity in sensitizing tumor cells to anticancer therapeutics, defibrotide presents an encouraging 
profile of biological effects that warrant further evaluation in clinical trials.  
Our results do not preclude additional potential mechanism(s) of antitumor effects of defibrotide. For 
instance, the effects of defibrote on veno-occlusive disease seem to occur via cytoprotective effects on liver 
sinusoidal endothelium and are related to the antithrombotic and profibrinolytic properties of defibrotide 
(as reviewed in ref. 3). Because there is evidence that procoagulation mechanisms, and in particular 
thrombin, may promote tumor progression and neoangiogenesis (46, 47), the demonstration that 
defibrotide antagonizes thrombin (48) suggests that thrombin inhibition may also contribute to the 
anticancer effect of defibrotide.  
The present study aimed at determining whether defibrotide would interfere with the anticancer effect of 
chemotherapy if administered concurrently with it. In view of the emerging role of defibrotide for the 
management of veno-occlusive disease and other vascular complications of cancer treatment, this question 
has direct implication to the future use of this agent in the context of patients with neoplasias. The results 
of this study show that defibrotide does not adversely interfere with the antitumor activity of many 
important classes of antineoplastic agents, with the exception of protection of tumor cells against 
doxorubicin. Interestingly, our results indicate that defibrotide has intriguing anticancer properties in its 
own right: in multiple in vivo tumor models that were tested, defibrotide confers a modest tumor growth 
delay as a single agent but also enhances the antitumor activity of several chemotherapeutic agents, 
including melphalan and cyclophosphamide. These results provide a rationale for clinical trials of 
defibrotide in the treatment of multiple myeloma and other neoplasias, as well as to a multicenter phase 
I/II study of melphalan, prednisone, thalidomide, and defibrotide in advanced multiple myeloma patients 
(49, 50).  
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